Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
Quoin Pharmaceuticals Up 28% On Plans To Start Second Trial To Evaluate QRX003 Topical Lotion
-
Bitcoin Price Could Easily Double Under CFTC-Led Regulation, Chair Rostin Behnam Reckons
-
Inflation Fears Keep World Markets Jittery
-
Hibbett Shares Rally On Better-than-estimated Earnings, Increased Outlook
-
Recent Survey Shows Investors Think BTC Is More Likely To Crash To $10,000 First Than Hit $30,000